What is the injectable winstrol dosage?
| Product | Strength | Form |
|---|---|---|
| Veterinary stanozolol injection2 | 50 mg per mL | Suspension |
| Winstrol label (RxList copy)1 | 2 mg per tablet | Oral tablet |
What the sources say about supply and strength
The table is set at the top of the page
The searches run (DailyMed, the RxList label and the veterinary regulation) found no human injectable vial size or strength, and makers' leaflets were not searched.
Label and trial doses
For hereditary angioedema, the oral tablet label says the dosage is individualized on the basis of the patient's clinical response, starting at 2 mg three times a day and, after a favorable initial response, decreasing at intervals of one to three months to a maintenance dosage of 2 mg a day.1 It also says some patients may be successfully managed on a 2 mg alternate day schedule, and that the use of anabolic steroids may be associated with serious adverse reactions, many of which are dose related.1 The saved human studies are Sheffer 1981 and Sloane 2007 in hereditary angioedema, Parsad 2001 in chronic refractory urticaria and Liu 2021 in high-risk myelodysplastic syndrome; none of the four reports describes an injection.3456
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Sheffer 19813 | 0.5 to 2 mg daily, the minimal effective dose reached | 27 patients (12 male, 15 female) with hereditary angioedema | 2 years |
| Parsad 20015 | Group A: 2 mg twice daily with cetirizine 10 mg daily; group B: cetirizine 10 mg daily with placebo tablets twice daily | 58 patients with chronic refractory urticaria (26 in group A and 24 in group B evaluated) | 12 weeks to assessment |
| Sloane 20074 | 0.5 to 2.0 mg daily, the minimal initial effective dosage, with dose and frequency later decreased in most patients | 21 patients with hereditary angioedema | Treated for 20 to 40 years |
| Liu 20216 | Stanozolol with decitabine (stanozolol dose not given), against decitabine alone | 62 patients with high-risk MDS (21 stanozolol, 41 control) | Median 6 (2-11) maintenance cycles, against 5 (2-12) in the control group |
Sheffer 1981 reported that higher doses of 4 mg/day were unnecessary for control of clinical disease and unjustified for chronic therapy because of more frequent side effects.3 No Milligram logged figure is available for this compound, so no logged dose, schedule or vial is shown.
Route, site and length
The label describes oral tablets, and oral administration is the route it states.1 For animals, the veterinary regulation gives deep intramuscular injection in the thigh at weekly intervals for several weeks for dogs and cats, and in the gluteal region weekly for not more than 4 weeks for horses.2 No saved human label or trial states an injection site; the human reports of injection found were case reports, not dose sources.7
Storage
The label says to store the tablets at controlled room temperature, 15° to 30° C (59° to 86° F).1 That covers the tablets only; no storage condition for an injectable, before or after mixing, appears in the sources read.
Frequently asked questions
Does injectable winstrol need mixing?
The veterinary regulation describes a suspension, with each milliliter containing 50 milligrams of stanozolol; no saved source gives mixing or water for mixing.2
How do you turn a dose in mg into mL and units?
The only concentration sourced is the veterinary 50 mg/mL, and no human product concentration is saved, so no mL or syringe mark is given.2 At any strength, the volume in mL is the dose in mg divided by the strength in mg per mL, and each unit on a U-100 syringe is a hundredth of a mL; no saved source pairs a human dose with an injectable strength.
What cycle length do sources state for injectable winstrol?
No saved human source gives a cycle length for injectable use; the veterinary regulation gives weekly injections for not more than 4 weeks for horses and for several weeks for dogs and cats.2
References
- RxList. Winstrol (Anabolic steroids): Side Effects, Uses, Dosage, Interactions, Warnings. 2021. rxlist.com
- US Code of Federal Regulations (21 CFR 522.2150, Cornell LII). 21 CFR § 522.2150 - Stanozolol. 2026. law.cornell.edu
- The Journal of allergy and clinical immunology (PubMed abstract). Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. 1981. pubmed.ncbi.nlm.nih.gov
- The Journal of allergy and clinical immunology (PubMed abstract). Hereditary angioedema: Safety of long-term stanozolol therapy. 2007. pubmed.ncbi.nlm.nih.gov
- The Journal of dermatology (PubMed abstract). Stanozolol in chronic urticaria: a double blind, placebo controlled trial. 2001. pubmed.ncbi.nlm.nih.gov
- International journal of hematology (PubMed abstract). Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment. 2021. pubmed.ncbi.nlm.nih.gov
- Journal of athletic training (PubMed abstract). Rhabdomyolysis of the deltoid muscle in a bodybuilder using anabolic-androgenic steroids: a case report. 2009. pubmed.ncbi.nlm.nih.gov